These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26837773)

  • 1. Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.
    Gui SL; Teng LC; Wang SQ; Liu S; Lin YL; Zhao XL; Liu L; Sui HY; Yang Y; Liang LC; Wang ML; Li XY; Cao Y; Li FY; Wang WQ
    Int Urol Nephrol; 2016 May; 48(5):701-9. PubMed ID: 26837773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.
    Xin H; Cao Y; Shao ML; Zhang W; Zhang CB; Wang JT; Liang LC; Shao WW; Qi YL; Li Y; Zhang ZY; Yang Z; Sun YH; Zhang PX; Jia LL; Wang WQ
    Int Urol Nephrol; 2018 May; 50(5):861-868. PubMed ID: 29524043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL3 overexpression promotes the tumorigenic potential of uterine cervical cancer cells via the MAPK/ERK pathway.
    Qi YL; Li Y; Man XX; Sui HY; Zhao XL; Zhang PX; Qu XS; Zhang H; Wang BX; Li J; Qi SF; Jia LL; Luan HY; Zhang CB; Wang WQ
    J Cell Physiol; 2020 May; 235(5):4756-4765. PubMed ID: 31667838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of CXCL3 in colon cancer promotes malignant behaviors of tumor cells in an ERK-dependent manner.
    Cheng Y; Yang X; Liang L; Xin H; Dong X; Li W; Li J; Guo X; Li Y; He J; Zhang C; Wang W
    BMC Cancer; 2023 Nov; 23(1):1162. PubMed ID: 38031087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
    Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
    Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth.
    Wang W; Li Y; Li Y; Hong A; Wang J; Lin B; Li R
    Int J Cancer; 2009 Feb; 124(3):521-30. PubMed ID: 18975380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis.
    Mochizuki H; Matsubara A; Teishima J; Mutaguchi K; Yasumoto H; Dahiya R; Usui T; Kamiya K
    Biochem Biophys Res Commun; 2004 Jul; 320(3):656-63. PubMed ID: 15240098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
    Maxwell PJ; Neisen J; Messenger J; Waugh DJ
    Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.
    Engl T; Relja B; Blumenberg C; Müller I; Ringel EM; Beecken WD; Jonas D; Blaheta RA
    Life Sci; 2006 Mar; 78(16):1784-93. PubMed ID: 16263140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation.
    Tsai CY; Lee TS; Kou YR; Wu YL
    J Cell Biochem; 2009 Oct; 108(2):489-98. PubMed ID: 19626664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
    Jin Y; Cui Z; Li X; Jin X; Peng J
    Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
    Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
    J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
    Gregg JL; Brown KE; Mintz EM; Piontkivska H; Fraizer GC
    BMC Cancer; 2010 Apr; 10():165. PubMed ID: 20426842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury.
    Piotrowska A; Rojewska E; Pawlik K; Kreiner G; Ciechanowska A; Makuch W; Nalepa I; Mika J
    Front Immunol; 2019; 10():2198. PubMed ID: 31616413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
    Barrett CS; Millena AC; Khan SA
    Prostate; 2017 Jan; 77(1):72-81. PubMed ID: 27604827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells regulate the proliferation of T cells via the growth-related oncogene/CXC chemokine receptor, CXCR2.
    Lee YS; Won KJ; Park SW; Lee HW; Kim B; Kim JH; Kim DK
    Cell Immunol; 2012 Sep; 279(1):1-11. PubMed ID: 23023221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
    Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
    Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
    Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.